Log In Sign up
The largest database of trusted experimental protocols

Cellcept intravenous

Manufactured by Roche
Visit Supplier
Sourced in United States

Cellcept Intravenous is a medical product used in the treatment of certain medical conditions. It is administered intravenously and is designed to assist in the management of these conditions. The core function of this product is to provide a treatment option for healthcare professionals, but a detailed description while maintaining an unbiased and factual approach is not available.

Automatically generated - may contain errors

Lab products found in correlation

Prograf, by Astellas Pharma (2 mentions)

2 protocols using cellcept intravenous

1

Immunosuppression prior to Ureaplasma challenge

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were pharmacologically immunosuppressed using intraperitoneal (IP) mycophenolate mofetil (90 mg/kg) (Cellcept Intravenous, Roche Laboratories, Inc., Nutley, NJ), IP tacrolimus (1.2 mg/kg) (Prograf, Astellas Pharma US, Inc., Northbrook, IL), and oral prednisone (6 mg/kg) (Prednisone Intensol, Roxane Laboratories, Inc., Columbus, OH) administered daily for seven days prior to challenge with U. urealyticum and continued over six days of microbial challenge (i.e., until the day before sacrifice).
Wang X., Karau M.J., Greenwood-Quaintance K.E., Block D.R., Mandrekar J.N., Cunningham S.A, & Patel R. (2016). Ureaplasma urealyticum Causes Hyperammonemia in an Experimental Immunocompromised Murine Model. PLoS ONE, 11(8), e0161214.
+ Open protocol
+ Expand
2

Immunosuppression Model for U. parvum Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were pharmacologically immunosuppressed using intraperitoneal (IP) mycophenolate mofetil (90 mg/kg) (Cellcept Intravenous, Roche Laboratories, Inc., Nutley, NJ), IP tacrolimus (1.2 mg/kg) (Prograf, Astellas Pharma US, Inc., Northbrook, IL), and oral prednisone (6 mg/kg) (Prednisone Intensol, Roxane Laboratories, Inc., Columbus, OH) administered daily for seven days prior to challenge with U. parvum and continued over six days of microbial challenge (i.e., until the day before sacrifice).
Wang X., Greenwood-Quaintance K.E., Karau M.J., Block D.R., Mandrekar J.N., Cunningham S.A., Mallea J.M, & Patel R. (2016). Ureaplasma parvum Causes Hyperammonemia in a Pharmacologically Immunocompromised Murine Model. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 36(3), 517-522.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!